A&O Shearman advises on Novonesis' €1.7bn triple-tranche debut Eurobond issuance

"A&O Shearman advised the dealers and managers on Danish biotech Novonesis’ establishment of a euro medium term note (EMTN) program and its debut triple‑tranche Eurobond issuance of EUR 1.7bn. The bonds (3-, 7- and 11‑year maturities) were rated A‑ by S&P and will help refinance the bridge facility used in the 2024 Novozymes–Chr. Hansen merger. The deal was completed successfully despite volatile market conditions. The A&O Shearman team was led by partner Peter Crossan, with Anne Low, Jacob Sewell and Anisa Khan."

A&O Shearman advised the dealers and the managers in connection with Novonesis’ euro medium term note (EMTN) programme and the subsequent Eurobond issuance. The transaction comprised the establishment of an EMTN programme followed by a triple‑tranche debut Eurobond placement totalling EUR 1.7 billion across 3‑, 7‑ and 11‑year maturities (rated A‑ by S&P). Proceeds will be used, among other things, to refinance the bridge facility put in place in connection with the Novozymes/Chr. Hansen merger in 2024; the bonds were successfully priced in volatile market conditions. The A&O Shearman team advising on the matter comprised: Peter Crossan (Partner, London), Anne Low (Senior Associate, London), Jacob Sewell (Senior Associate, London) and Anisa Khan (Associate, London).

Menu

A&O Shearman advises on Novonesis' €1.7bn triple-tranche debut Eurobond issuance

Read the full story

Menu

A&O Shearman advises on Novonesis' €1.7bn triple-tranche debut Eurobond issuance

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads